Call for applications for a fully financed PhD fellowship
The applicant will join an active research group conducting randomized and observational trials in patients with hypertrophic cardiomyopathies
Hypertrophic cardiomyopathy (HCM) is a heart muscle disease associated with life-long symptoms and risk of sudden cardiac death.
The research group currently conduct a state of the art, blinded and placebo controlled triple cross over trial to analyze the treatment effects of the two recommended drugs (beta-blockers and calcium channel blockers) against placebo. The TEMPO II trial. The recommended treatments have not been evaluated according to modern scientific standards in HCM. New well-documented HCM-specific drugs, in pipeline, are expected to be expensive, and no head-to-head studies have been published. This study will deliver detailed information on various treatment effects of two frequently prescribed drugs for HCM.
Phase one of the trial will evaluate treatment effects exercise capacity, symptoms, and echocardiographic meassures will be concluded by december 2024.
Phase two will run for further 2.5 years and evaluate myocardial function and remodelling using cardiac magnetic resonance imaging
Phase three will run for further 2.5 years and evaluate the anti arrythmic treatment effects using Holter-monitoring
The PhD student will be engaged in Phase two and three, and be responsible for patient inclusion evaluation data collection, analyses and publication. Additionally the PhD student will be involved n development og future observational and randomized trials.
The PhD student will collaborate with several clinics within the department of cardiology, AUH in a team of research nurses, secretaries and physicians.
We are looking for at phycisian with a clear interest cardiology, a future colleague that is able to manage and push the project forward, a scientific mind searching for answers that will benefit future patients.
Supervisors are established researcher within the field of genetic cardiomyopathies and heart failure.
Applicant must have:
We prioritize applicants with:
Please submit your application via this link. Application deadline is 8 January 2025 23:59 CET. Preferred starting date: 1 March 2025.
For information about application requirements and mandatory attachments, please see our application guide.
Please contact Clinical Associate Professor Morten Steen Kvistholm Jensen, mortenjensen@clin.au.dk, for more information.
All interested candidates are encouraged to apply, regardless of their personal background. Salary and terms of employment are in accordance with applicable collective agreement.
